You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novo Nordisk A/S (NVO) - free report >>
Eli Lilly and Company (LLY) - free report >>
Amplify Weight Loss Drug & Treatment ETF (THNR) - free report >>
Image: Bigstock
Weight Loss Drug ETF (THNR) Hits New 52-Week High
Amplify Weight Loss Drug & Treatment ETF (THNR - Free Report) is probably on the radar for investors seeking momentum. The fund just hit a 52-week high and moved up 51.9% from its 52-week low price of $18.56/share.
Are more gains in store for this ETF? Let us take a quick look at the fund and the near-term outlook on it to get a better idea of where it might be headed.
THNR in Focus
The underlying VettaFi Weight Loss Drug & Treatment Index comprises of global companies who are manufacturers in the GLP-1 agonist pharmaceutical business or who enable such business. The product charges 59 bps in annual fees.
Why the Move?
Weight-loss drug market has been in a hot pot lately. The ETF has large weights in Novo Nordisk (NVO - Free Report) and Eli Lilly (LLY - Free Report) . Both stocks have an individual weight of more than 10% of the fund. With each of the stocks gaining more than 2% on May 30, 2025, the fund had every reason to surge.
More Gains Ahead?
The ETF THNR might falter on its strong performance in the near term, with a negative weighted alpha of 12.86.